Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators

Xiaomin Liu,Yu Zhang,Hongyuan Duan,Lei Yang,Chao Sheng,Zeyu Fan,Ya Liu,Ying Gao,Xing Wang,Qing Zhang,Zhangyan Lyu,Fangfang Song,Fengju Song,Yubei Huang
DOI: https://doi.org/10.1186/s40001-023-01228-x
IF: 4.981
2023-07-27
European Journal of Medical Research
Abstract:Although prostate-specific antigen (PSA) is widely used in prostate cancer (PCa) screening, nearly half of PCa cases are missed and less than one-third of cases are non-lethal. Adopting diagnostic criteria in population-based screening and ignoring PSA progression are presumed leading causes.
medicine, research & experimental
What problem does this paper attempt to address?